Le Lézard
Classified in: Health, Science and technology, Business
Subject: ERN

RhoVac Reports Interim Results on Immunological Response with RV001


STOCKHOLM, Nov. 18, 2019 /PRNewswire/ -- Today, 18th November 2019, RhoVac AB ("RhoVac") reports interim results from ongoing immunological studies at University of Tübingen, Germany concluding that treatment with RV001 can activate CD4+ T-cells and also CD8+ T-cells.

In July 2019 RhoVac published results on the follow-up phase of the phase I/II clinical study and in relation to the immunological response it could be concluded that 18 patients showing significant treatment related immunological response at completion of treatment. All 18 patients still showed significant response at 3-, 6- and 9-months follow-up. At the 12-months follow-up, 17 out of the 18 responding patients still showed significant immunological response.

Ongoing immunological studies at the University of Tübingen now confirm that treatment with RV001 can activate CD4+ T-cells and also CD8+ T-cells. Confirmation that the drug candidate RV001 can activate CD4+ T cells is important for the clinical value of the treatment. This has been demonstrated in a number of scientific publications of which some are referenced below:

For these reasons the MHC class II tumor antigen presentation pathway (the pathway linked to CD4+ T cells) must be utilized for therapeutic cancer vaccines to have a high clinical value, and interim results strongly indicate that RV001 is well capable of this.

Comment from RhoVac's CEO, Anders Månsson: 

- Confirmation of the immunological response concluded based on interim results is obviously important data for the ongoing development of the drug candidate RV001. I am looking forward to the continued collaboration with the team at University of Tübingen.

For further information, please contact:

Anders Månsson ? CEO, RhoVac AB
Phone number: +46 73-751 72 78
E-mail: [email protected]

This information is such that RhoVac AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on 18th November 2019.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/rhovac/r/rhovac-reports-interim-results-on-immunological-response-with-rv001,c2966819

The following files are available for download:

https://mb.cision.com/Main/13747/2966819/1146023.pdf

Release

SOURCE RhoVac


These press releases may also interest you

at 04:10
Storytel's Annual Report and Sustainability Report 2023 is now published and available as a downloadable PDF document on our website.  FNCA Sweden AB is the Company's Certified Adviser. For more information, please contact:Mattias Frithiof, Head of...

at 04:00
Yukon Group, Europe's leading thermal imaging and night vision company, has launched the world's first upgradable thermal monocular for civilian use. The Pulsar Telos LRF XP50 is set to become an indispensable tool for hunters, explorers and rescuers...

at 04:00
Growing Bolder, a leading lifestyle content producer, and OTT Advisors (OTTA), a leading advisory service for digital strategy, are partnering to launch the world's first active-lifestyle streaming platform for the world's fastest-growing and most...

at 03:40
KLab Inc. announced that its hit 3D action game Bleach: Brave Souls will be holding the Thousand-Year Blood War Zenith Summons: Reinforcements from Sunday, March 31. See the original press release (https://www.klab.com/en/press/) for more...

at 03:30
Electric vehicles (EVs) are a primary method to reach a net zero transportation sector, but in addition to CO2 emissions, overall sustainability is becoming an increased focus point. However, sustainability is a very complex topic that does not tend...

at 03:30
Vicore Pharma Holding (STO:VICO)Sessions at ATS to include an oral late-breaking presentation of the final results from the Phase 2a AIR trial of buloxibutid (C21) in IPFAdditional presentations include preclinical and translational data reflecting...



News published on and distributed by: